Epilepsy Medication or Device Denied by Insurance? How to Appeal

Epilepsy affects approximately 3.4 million Americans. Nearly one-third develop drug-resistant epilepsy (DRE) — requiring newer medications or neurostimulation devices that insurers routinely deny. Uncontrolled seizures carry severe consequences: SUDEP risk, driving restrictions, employment loss, and repeated hospitalizations. The good news is that these denials are frequently overturnable when the right clinical and legal arguments are made.

Why Insurers Deny Epilepsy Treatments

Step therapy not completed. The insurer requires failure of additional older AEDs before approving newer agents, even when DRE criteria under the ILAE 2010 definition (failure of two or more adequate AED trials) are already met. This is the most common and most directly challengeable denial for newer AEDs like Xcopri, Briviact, Vimpat, and Epidiolex.

Not medically necessary. A utilization reviewer — often lacking neurology specialty expertise — overrides the treating neurologist's selection. AAN Practice Guidelines exist precisely to establish evidence-based standards that contradict these determinations.

Experimental or investigational. Applied to FDA-approved medications and devices in clinical use for years. Denying VNS (FDA-approved since 1997) or Epidiolex (FDA-approved 2018) as experimental is factually indefensible and directly contradicted by AAN guidelines.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained. Required for brand-name AEDs and all neurostimulation devices (VNS, RNS, DBS). If authorization lapsed between approval and the procedure, the claim may be denied regardless of clinical appropriateness.

Documentation insufficient. Records do not explicitly reference the ILAE DRE criteria or AAN practice guidelines. Accurate ICD-10 coding is critical: intractable epilepsy codes (G40.019, G40.119, G40.311) directly signal DRE severity to reviewers.

How to Appeal

Step 1: Request the Insurer's Clinical Policy Bulletin

Request the CPB for the denied treatment immediately. This document specifies exactly what criteria must be met. Under ERISA 29 CFR § 2560.503-1 and ACA 45 CFR § 147.136, you are legally entitled to this document.

Step 2: Establish ILAE DRE Criteria in Writing

Have your neurologist explicitly document using ILAE 2010 language: the patient has failed two or more adequately dosed, appropriate AED schedules. List each prior AED with dose, duration, and reason discontinued. This establishes that step-therapy requirements are already satisfied.

Step 3: Build the Clinical Evidence Package

For step-therapy denials, demonstrate prior failures meet ILAE DRE criteria. For experimental denials, cite FDA approval date, AAN guideline support, and published trial data — REDUCE trial (21% seizure-free rate for cenobamate), GWCARE1 (Epidiolex in Dravet/LGS), PACE and CLASS studies (VNS), 2013 REDUCE trial (54% median seizure reduction for RNS at five-plus years), and SANTE trial (40% seizure reduction at three months, 69% at five years for DBS). For medical necessity denials, cite SUDEP risk from uncontrolled tonic-clonic seizures and functional impairment.

Step 4: Request Peer-to-Peer Review

Your neurologist should speak directly with the insurer's medical director. Non-specialist reviewers often issue epilepsy denials — a neurologist-to-neurologist conversation frequently resolves these cases without further escalation.

Step 5: Submit and Track

Send by certified mail and through the insurer's portal with delivery confirmation. Track the insurer's response deadline: 30 days for pre-service, 60 days for post-service under ACA regulations; 72 hours for urgent expedited appeals.

Step 6: Escalate if Denied

Request free External Independent Review: Complete Guide" class="auto-link">external review — an independent physician evaluates the clinical evidence with no insurer affiliation. ACA external review decisions are binding on the insurer. For ERISA employer plans, after exhausting internal appeals you may file in federal court under ERISA § 502(a)(1)(B). The administrative record built during internal appeals is the foundation for any federal court case.

What to Include in Your Appeal

• Denial letter with specific reason code and policy provision cited
• Neurologist letter citing ICD-10 G40.x intractable code, ILAE DRE classification, and AAN guidelines
• Complete AED trial history: drug name, dose, duration, and reason discontinued for each trial
• Clinical trial data supporting the denied treatment (specific trial name and key findings)
• SUDEP risk statement if applicable — especially for uncontrolled tonic-clonic seizures
• Documentation of functional impact: driving restrictions, employment effects, safety risks

Fight Back With ClaimBack

Epilepsy treatment denials require precise clinical documentation — ILAE DRE criteria, AAN guideline citations, ICD-10 G40.x intractable coding, and clinical trial data for the specific medication or device denied. ClaimBack generates a professional appeal letter in 3 minutes, incorporating the correct clinical and legal arguments for your specific denial. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal